CorMedix (CRMD) Set to Announce Earnings on Wednesday

Key Points

• CorMedix is scheduled to report Q3 2026 results before the market opens November 11. Analysts forecast a loss of $0.09 per share and revenue of $52.77 million; a conference call is scheduled for November 12 at 7:00 a.m. ET.
• In its most recent reported quarter, CorMedix earned $0.29 per share and generated $101.93 million in revenue, beating analyst estimates for both.
• Analysts maintain a Moderate Buy consensus rating, with an average price target of $14.62. Recent targets range from $12 to $15, while the stock opened at $5.56.

CorMedix (NASDAQ:CRMD - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect CorMedix to post earnings of ($0.09) per share and revenue of $52.77 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 7:00 AM ET.

CorMedix (NASDAQ:CRMD - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.05. The company had revenue of $101.93 million during the quarter, compared to the consensus estimate of $96.04 million. CorMedix had a return on equity of 40.52% and a net margin of 40.49%. On average, analysts expect CorMedix to post $0.54 EPS for the current fiscal year and $0.13 EPS for the next fiscal year.

CorMedix Stock Up 3.2%

Shares of CRMD opened at $5.56 on Wednesday. CorMedix has a 1 year low of $5.30 and a 1 year high of $13.02. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.56 and a quick ratio of 2.36. The stock has a 50 day simple moving average of $7.69 and a two-hundred day simple moving average of $7.65. The firm has a market cap of $433.35 million, a P/E ratio of 2.60, a P/E/G ratio of 1.01 and a beta of 1.48.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CRMD shares. Needham & Company LLC cut their price objective on shares of CorMedix from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Monday. Royal Bank Of Canada lifted their target price on shares of CorMedix from $13.00 to $14.00 and gave the stock an "outperform" rating in a research report on Friday, August 14th. Oppenheimer began coverage on shares of CorMedix in a research report on Wednesday, September 23rd. They issued an "outperform" rating and a $15.00 target price on the stock. Finally, Weiss Ratings raised shares of CorMedix from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $14.62.

About CorMedix

CorMedix Inc is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat life-threatening infections and inflammatory conditions. The company's lead product is DefenCath, a catheter-lock solution containing taurolidine and citrate.

DefenCath is approved by the U.S. Food and Drug Administration for use in adult patients with kidney failure who are receiving chronic hemodialysis through a central venous catheter. It is intended to reduce the risk of catheter-related bloodstream infections, a significant complication for patients who depend on long-term vascular access.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.